{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2024:RIY2L37RMYI5QZ2OGJ2Z7AQKFT","short_pith_number":"pith:RIY2L37R","schema_version":"1.0","canonical_sha256":"8a31a5eff16611d8674e32759f820a2cd6fbfb3c98be0de4f9c45b673e7a7b5a","source":{"kind":"arxiv","id":"2404.11406","version":1},"attestation_state":"computed","paper":{"title":"Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":["stat.CO"],"primary_cat":"stat.AP","authors_text":"Arnab Kumar Maity, Lada Markovtsova, Ray Li, Roberto Bugarini, Satrajit Roy Chowdhury","submitted_at":"2024-04-17T14:09:39Z","abstract_excerpt":"Oncology drug development starts with a dose escalation phase to find the maximal tolerable dose (MTD). Dose limiting toxicity (DLT) is the primary endpoint for dose escalation phase. Traditionally, model-based dose escalation trial designs recommend a dose for escalation based on an assumed dose-DLT relationship. Pharmacokinetic (PK) data are often available but are currently only used by clinical teams in a subjective manner to aid decision making. Formal incorporation of PK data in dose-escalation models can make the decision process more efficient and lead to an increase in precision. In t"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2404.11406","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.AP","submitted_at":"2024-04-17T14:09:39Z","cross_cats_sorted":["stat.CO"],"title_canon_sha256":"281580abf2bfcf11179b5f7930c07c96ffb109fa9409485a4d351faec2bcc18c","abstract_canon_sha256":"f0ffaf4d22549f610f18049b56dd7790a13fc14c504bc64c71bd19e773e9126a"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T08:09:08.402525Z","signature_b64":"3hDnTLdpO7ml86+a7D0bbnOju1NK9LqTxMLNvpvuY3wPmNSd+/RcyWw/Bd6+yg25+6affMwLlKFa/4UfYp3aAA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"8a31a5eff16611d8674e32759f820a2cd6fbfb3c98be0de4f9c45b673e7a7b5a","last_reissued_at":"2026-07-05T08:09:08.402070Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T08:09:08.402070Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":["stat.CO"],"primary_cat":"stat.AP","authors_text":"Arnab Kumar Maity, Lada Markovtsova, Ray Li, Roberto Bugarini, Satrajit Roy Chowdhury","submitted_at":"2024-04-17T14:09:39Z","abstract_excerpt":"Oncology drug development starts with a dose escalation phase to find the maximal tolerable dose (MTD). Dose limiting toxicity (DLT) is the primary endpoint for dose escalation phase. Traditionally, model-based dose escalation trial designs recommend a dose for escalation based on an assumed dose-DLT relationship. Pharmacokinetic (PK) data are often available but are currently only used by clinical teams in a subjective manner to aid decision making. Formal incorporation of PK data in dose-escalation models can make the decision process more efficient and lead to an increase in precision. In t"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2404.11406","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2404.11406/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2404.11406","created_at":"2026-07-05T08:09:08.402119+00:00"},{"alias_kind":"arxiv_version","alias_value":"2404.11406v1","created_at":"2026-07-05T08:09:08.402119+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2404.11406","created_at":"2026-07-05T08:09:08.402119+00:00"},{"alias_kind":"pith_short_12","alias_value":"RIY2L37RMYI5","created_at":"2026-07-05T08:09:08.402119+00:00"},{"alias_kind":"pith_short_16","alias_value":"RIY2L37RMYI5QZ2O","created_at":"2026-07-05T08:09:08.402119+00:00"},{"alias_kind":"pith_short_8","alias_value":"RIY2L37R","created_at":"2026-07-05T08:09:08.402119+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT","json":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT.json","graph_json":"https://pith.science/api/pith-number/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/graph.json","events_json":"https://pith.science/api/pith-number/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/events.json","paper":"https://pith.science/paper/RIY2L37R"},"agent_actions":{"view_html":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT","download_json":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT.json","view_paper":"https://pith.science/paper/RIY2L37R","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2404.11406&json=true","fetch_graph":"https://pith.science/api/pith-number/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/graph.json","fetch_events":"https://pith.science/api/pith-number/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/action/timestamp_anchor","attest_storage":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/action/storage_attestation","attest_author":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/action/author_attestation","sign_citation":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/action/citation_signature","submit_replication":"https://pith.science/pith/RIY2L37RMYI5QZ2OGJ2Z7AQKFT/action/replication_record"}},"created_at":"2026-07-05T08:09:08.402119+00:00","updated_at":"2026-07-05T08:09:08.402119+00:00"}